TG Therapeutics Reports Q3 2026 Revenue Growth Driven by BRIUMVI Sales
TG Therapeutics (TGTX) reported strong third-quarter 2026 financial results, highlighted by total global revenue of $259.9 million, a 61% increase year-over-year. This growth was primarily fueled by the robust performance of BRIUMVI in the U.S., which generated $232.6 million in net product revenue, up 52% compared to the same period last year. Driven by increased physician adoption and a rising mix of treatment-naive patients, management raised its full-year U.S. BRIUMVI revenue guidance to a range of $915 million to $920 million. The company also reached a significant milestone by projecting full-year global revenue to hit $1 billion, less than four years after the product's initial launch.
Tickers: $TGTX
Topics: gross margin guidance raise operating income revenue growth
Read the full article at Motley Fool
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)